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Abstract
Previously, we have shown that a maternal low protein diet, fed exclusively during the preimplantation period of mouse
development (Emb-LPD), is sufficient to induce by the blastocyst stage a compensatory growth phenotype in late gestation
and postnatally, correlating with increased risk of adult onset cardiovascular disease and behavioural dysfunction. Here, we
examine mechanisms of induction of maternal Emb-LPD programming and early compensatory responses by the embryo.
Emb-LPD induced changes in maternal serum metabolites at the time of blastocyst formation (E3.5), notably reduced insulin
and increased glucose, together with reduced levels of free amino acids (AAs) including branched chain AAs leucine,
isoleucine and valine. Emb-LPD also caused reduction in the branched chain AAs within uterine fluid at the blastocyst stage.
These maternal changes coincided with an altered content of blastocyst AAs and reduced mTORC1 signalling within
blastocysts evident in reduced phosphorylation of effector S6 ribosomal protein and its ratio to total S6 protein but no
change in effector 4E-BP1 phosphorylated and total pools. These changes were accompanied by increased proliferation of
blastocyst trophectoderm and total cells and subsequent increased spreading of trophoblast cells in blastocyst outgrowths.
We propose that induction of metabolic programming following Emb-LPD is achieved through mTORC1signalling which
acts as a sensor for preimplantation embryos to detect maternal nutrient levels via branched chain AAs and/or insulin
availability. Moreover, this induction step associates with changes in extra-embryonic trophectoderm behaviour occurring
as early compensatory responses leading to later nutrient recovery.
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Introduction
Periconceptional environment has been shown to influence the
subsequent programme of development in animal models with
long-lasting consequences affecting the physiology and health
status of offspring [1–5]. Thus, in rodents, culture conditions in
vitro [6–13] and maternal dietary protein restriction in vivo [14–
17] during preimplantation development are associated with
abnormal postnatal growth and increased adult-onset disease risk,
characterized particularly in cardiovascular, metabolic and
behavioural dysfunction. Similar phenomena have also been
observed in related ruminant embryo models [18–21]. Collective-
ly, these environmental sensitivities of early developmental stages
provide support for an important component of the ‘Develop-
mental Origins of Health and Disease’ (DOHaD) hypothesis,
derived from epidemiological and experimental datasets, propos-
ing increased susceptibility to chronic diseases in later life from a
deprived in utero experience [22–25]. Embryo environment
effects also have implications for the safety of assisted conception
practices [26–29].
Our recent work using the mouse protein restriction model has
demonstrated that mothers fed a low protein diet (9% casein)
exclusively during the preimplantation period (E0-3.5; Emb-LPD)
generated offspring displaying life-long hypertension compared
with controls, and associated with attenuated arterial vasodilata-
tion, elevated lung angiotensin-converting enzyme activity, hyper-
active behavior and increased adiposity [15–17]. Our data also
indicated that an early response to this transient dietary challenge
(or following LPD maintained throughout gestation) concerned
activation of compensatory mechanisms to stabilize later growth of
the conceptus. This included evidence of enhanced maternal-fetal
nutrient transport capacity via the visceral yolk sac in late gestation
and a corresponding increase both in conceptus and birth weight
following maternal Emb-LPD [15]. Moreover, the early induction
of growth compensation appeared critical in the later onset of
disease since Emb-LPD offspring perinatal weight correlated
positively with adult weight and susceptibility to cardiovascular
and behavioural disease [15].
The current study is concerned with the mechanisms of
induction of adverse developmental programming using this
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model and the early steps in compensatory responses. We believe
induction has occurred by the blastocyst stage since transfer of
blastocysts collected from Emb-LPD mothers into recipients fed
control diet before and subsequent to transfer exhibit the
characteristic enhanced growth phenotype in late gestation [15].
Past studies have identified a plethora of communication processes
operate within the post-conception maternal tract regulating
embryo developmental progression and differentiation, immune
system modulation and synchronization of implantation, com-
monly mediated by a range of steroid hormones, growth factors
and cytokines [30–35]. Whilst none of these signalling mechanisms
can be excluded from a role in ‘nutrient sensing’ by the embryo,
we anticipate that the key factors involved are directly growth
regulatory given the association between conceptus growth and
later disease discussed above. We focus on the potential role of
insulin and amino acid (AA) levels as signaling components
involved in nutrient sensing. Both of these factors act to control
proliferation and cellular phenotype during early development
with long-lasting positive effects on fetal growth [36–42]. Insulin
and the branched chain AAs, especially leucine, also contribute to
cellular growth though intracellular mTORC1 signalling [43–45].
Moreover, mTORC1 has previously been implicated a role in
mouse blastocyst trophoblast motility [38,40].
We have evaluated the effect of Emb-LPD treatment on mouse
maternal systemic and reproductive tract physiology and embryo
development and phenotype up to the time of implantation. In
particular, we focus on dietary effects on AA availability within the
maternal circulation and uterine fluid and within blastocysts. We
also evaluate the effect of diet on mTORC1 signalling within
blastocysts and examine potential compensatory mechanisms in
the blastocyst trophectoderm (TE) lineage. Collectively, our studies
indicate a potential role for AA and insulin metabolic signalling
through mTORC1 in the induction of blastocyst programming
with evidence of increased TE proliferation and invasive behavior
in a compensatory response by the time of implantation.
Results
Emb-LPD Alters the Composition of Maternal Serum
Metabolites
Serum metabolites from Emb-LPD and NPD mothers were
analysed at E3.5 and 4.5. Emb-LPD serum at E3.5 was depleted in
insulin and elevated in glucose (P,0.05; Figure 1A,B). Maternal
diet had no effect on corticosterone concentration (Figure 1C);
estrogen was increased at E4.5 (P,0.05; Figure 1D) while no
change was found in progesterone concentration (Figure 1E).
Emb-LPD Alters the Composition of Maternal and
Blastocyst Amino Acids
Serum AA composition in Emb-LPD and NPD mothers was
analysed at E2.5, 3.5 and 4.5 (Table 1) and further represented as
an aminogram with descending AA concentrations at these time
points (Figure 2A). No differences in individual AA concentration
were evident at E2.5 but at E3.5, alanine, histidine, isoleucine,
leucine, lysine, methionine, phenylalanine, tryptophan, tyrosine
and valine were all depleted (P,0.05 or lower) in Emb-LPD versus
NPD treatment with arginine depleted in Emb-LPD at trend level
(P,0.1). At E4.5, isoleucine, leucine, tyrosine and valine were
depleted in Emb-LPD versus NPD serum (P,0.05 or lower) while
asparagine, phenylalanine and threonine were depleted in Emb-
LPD at trend level (P,0.1) (Table 1). At E3.5, combined essential
AAs and branched chain AAs were depleted in the Emb-LPD
serum (P,0.01 or lower) while at E4.5, branched chain AAs were
depleted in Emb-LPD serum (P,0.05) and also essential and total
AAs depleted in Emb-LPD serum at trend level (P,0.1).
Comparing individual AA concentrations within a treatment
group across the time-course showed that several changed as
shown in Table 1 (indicated by same letter). The aminogram
(Figure 2A) further demonstrates changes in AA concentration
across the time course, especially the higher concentration AAs
(taurine, lysine, glutamine, alanine, glycine) rising transiently at
E3.5.
The AA concentration of uterine fluid (UF) was analysed with
respect to maternal diet at E2.5, 3.5 and 4.5 (Table 2, Figure 2B).
No differences were found between diet treatments for individual
AA concentrations at E2.5. At E3.5, the three branched chain
AAs, isoleucine, leucine and valine, both individually and
collectively, were depleted (P,0.05 or lower) in Emb-LPD versus
NPD UF. In addition, glycine, histidine, lysine, taurine and
threonine were depleted in Emb-LPD UF at trend level (P,0.1).
Both essential and non-essential AAs were depleted in Emb-LPD
UF (P,0.05). At E4.5, isoleucine, leucine and valine remained
depleted in Emb-LPD versus NPD UF (P,0.05 or lower) while
methionine was elevated (P,0.01) in Emb-LPD UF. As was found
with maternal serum, changes in concentration of several AAs
within treatment group were also evident across the time course
(Table 2 Figure 2B). The pattern of transient increase at E3.5 of
the higher concentration AAs in serum was not apparent in the UF
aminogram except for alanine (Figure 2B). Glycine concentration
was higher at E2.5 than E4.5 for both diet treatments (Figure 2B).
Collected blastocysts at E3.5 were rapidly washed and
immediately processed for AA composition (Table 3, Figure 2C).
This analysis revealed that the individual AA asparagine was
depleted (P,0.05) in concentration within Emb-LPD blastocysts
while hypotaurine, lysine and taurine were depleted in Emb-LPD
blastocysts at trend level (P,0.1). When individual AA concen-
trations were converted to relative % of total AAs, lysine and
taurine were depleted in Emb-LPD blastocysts (P,0.05), while
glutamic acid, phenylalanine (P,0.05), methionine (P,0.001) and
valine (P,0.1) were elevated (Table 3). Non-essential AAs were
depleted (P,0.05) and essential AAs increased (P,0.05) in relative
% total in Emb-LPD blastocysts.
The differing maternal (serum, UF) and blastocyst pools of AAs
exhibit marked changes in concentration with blastocysts showing
the highest concentration levels for most AAs. In Table 4 and
Figure 3, the fold change in concentration for individual and
grouped AAs between these pools is recorded for both NPD and
Emb-LPD treatments. AA composition of blastocysts and UF was
more similar compared to serum.
Emb-LPD Induces a Change in mTORC1 Signalling in
Blastocysts
Collectively, the maternal AA and metabolite studies revealed
reduced availability of insulin and branched chain AAs in response
to Emb-LPD at E3.5, during the period of blastocyst formation.
The mTORC1 pathway regulates protein translation and growth
rates within cells and is activated both by insulin and branched
chain AAs via PI3K and Akt [43–45]. We next investigated
whether the depleted nutrient environment following Emb-LPD
treatment influenced mTORC1 signalling within blastocysts. We
examined the expression and extent of phosphorylation of the
mTORC1 downstream targets S6 ribosomal protein (a translation
activator, mediated by S6 kinase phosphorylation, of terminal
oligopyrimidine (TOP)-dependent transcripts encoding ribosomal
proteins commonly involved in cell cycle progression and
translation regulation) [46,47] and 4E-BP1 (a translation repressor
protein that inhibits translation by binding to eIF4E translation
initiation factor, an interaction abolished by phosphorylation,
Mouse Blastocyst Developmental Programming
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e52791
leading to cap-dependent mRNA translation) [45] using quanti-
tative immunoblotting normalised to a-tubulin. Blastocysts derived
from NPD and Emb-LPD mothers exhibited equivalent amounts
of total S6 (Figure 4A–C) and 4E-BP1 (Figure 4D–F). However,
the pool of phosphorylated S6 within Emb-LPD blastocysts was
reduced as was the phosphorylated/total ratio (P,0.05) compared
with NPD blastocysts (Figure 4C). In contrast, the extent of
phosphorylation of 4E-BP1 was not altered by maternal diet
(Figure 4F). These data indicate that the reduced maternal insulin
and AA composition in Emb-LPD mothers is associated with
reduced mTORC1 signalling capacity by blastocysts.
Emb-LPD Leads to Change in Blastocyst Phenotype and
Outgrowth Potential
The number and stage of embryos collected from NPD and
Emb-LPD mothers after natural mating at E3.5 over several
experiments did not differ significantly (for example, embryos/
mouse: NPD 11.960.7, Emb-LPD 12.260.9; n= 13–15 mothers
per treatment). Similarly, the proportion of early, expanding and
hatching blastocysts at E3.5 was not significantly different across
treatments although the proportion of Emb-LPD blastocysts
expanding was slightly higher than NPD blastocysts (Figure 5A).
Blastocysts collected at E3.5 and 3.75 were analysed for
trophectoderm (TE) and inner cell mass (ICM) cell numbers. TE
and ICM cell numbers were equivalent at E3.5 but TE cell
numbers and total cell numbers were increased in response to
Emb-LPD at E3.75 (P,0.05; Figure 5B). Analysis of late morulae
(E3.25) or earlier stage embryos did not show cell number
differences between treatments (data not shown).
Blastocysts at E3.5 collected from Emb-LPD and NPD mothers
were cultured individually in a modified KSOM+FCS for up to 4
days during which hatching from the zona pellucida, attachment
Figure 1. Concentration of maternal serum metabolites at E3.5 and 4.5 following Emb-LPD and NPD treatments. (A) insulin, n = 11–16
per treatment; (B) glucose, n = 13–20 per treatment; (C) corticosterone, n = 11–16 per treatment; (D) estrogen, n = 6–11 per treatment; (E)
progesterone, n = 6–11 per treatment. * P,0.05.
doi:10.1371/journal.pone.0052791.g001
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to the culture surface and spreading of trophoblast cells from the
TE were monitored. KSOM was modified with the addition of 19
AAs at concentrations equivalent to those found within UF in
NPD mothers at E3.5 (KSOMufaa+FCS; see Table 2 for AA
composition) for both diet treatment groups. The capacity for
embryos to hatch, attach or initiate spreading over the culture
surface was not significantly different between treatment groups
(for example, % hatched, attached or spreading at 48 h and 72 h
culture: NPD 45.9610.4, 63.869.4; Emb-LPD 47.369.3,
62.168.2; n = 158–179 embryos/treatment). The spreading area
of individual outgrowths was measured at 48 h and 72 h culture.
This demonstrated no difference between treatments at 48 h but
at 72 h, outgrowths derived from Emb-LPD blastocysts had
spread over a larger area than those from NPD blastocysts
(P,0.05; Figure 5C,D). After 96 h, neither spreading area (NPD
59.965.4 and Emb-LPD 59.864.5 arbitrary units, n = 26–31) nor
number of nuclei (NPD 77.264.8 and Emb-LPD 7664.5 nuclei,
n = 27–33) were different between diet treatment and represented
when the cultures were no longer expanding in size. To determine
whether spreading capacity was regulated via the mTORC1
pathway, blastocyst outgrowths were analysed in the presence or
absence of rapamycin, an inhibitor of mTORC1. Rapamycin did
not inhibit hatching, attachment or flattening in preparation to
spread in either diet group. However, spreading during the 48–
72 h period was sensitive to rapamycin (20 mM but not 2 mM) in
NPD outgrowths (P,0.05) but was insensitive to rapamycin in the
Emb-LPD outgrowths at both concentrations (Figure 5E). Collec-
tively, these data indicate that maternal Emb-LPD induced
responses in embryos in vivo including increased TE proliferation
and subsequent increased trophoblast spreading capacity, and the
latter appeared to be independent of mTORC.
Discussion
In this study we have investigated the mechanisms by which
maternal Emb-LPD may initiate developmental programming
within the mouse blastocyst, shown previously to lead to adult
disease affecting cardiovascular, metabolic and behavioural
systems [15–17]. Given that adult disease risk following Emb-
LPD is positively correlated with an earlier compensatory response
of fetal growth stimulation induced by the blastocyst stage (see
Introduction; [15]), our attention has focused on signalling
pathways known to affect growth control during development.
Our analyses of the effects of the diet on maternal metabolites and
Table 1. Serum concentrations of free amino acids from mice fed either NPD or Emb-LPD at day 2.5, 3.5 or 4.5 of pregnancy.
Amino acid Concentration (mM)
2.5 days 3.5 days 4.5 days
Amino Acid NPD Emb-LPD NPD Emb-LPD NPD Emb-LPD
n 11 9 14–151 11 10 11
Alanine 0.37660.062 a 0.48360.061 0.52760.043 *b 0.39560.019 * 0.38660.031 0.33860.019
Arginine 0.13960.026 0.13260.016 0.17660.013 n 0.13960.015 n 0.16960.024 0.14060.170
Asparagine 0.04460.009 0.04060.005 0.04360.003 0.04160.003 0.04060.005 n 0.03160.003 n
Aspartic acid 0.05460.007 0.04960.009 0.04360.005 0.04460.006 0.04660.008 0.03560.003
Glutamic acid 0.13460.032 0.12260.029 b 0.18660.019 0.21060.021 a 0.15460.027 0.09660.008 b
Glutamine 0.39260.077 a 0.43760.066 0.58860.037 b 0.57860.043 a 0.47360.037 0.40760.029 a
Glycine 0.10860.020 b 0.10660.014 b 0.28660.027 a 0.27660.027 a 0.12360.110 b 0.11660.020 c
Histidine 0.04860.009 a 0.05360.007 0.07560.006 *b 0.05460.004 * 0.05460.005 0.04460.005
Isoleucine 0.10760.018 0.09360.012 0.11960.006 { 0.07960.007 { 0.10860.011 * 0.07660.010 *
Leucine 0.15060.024 0.12860.016 0.18360.009 { 0.12260.012 { 0.14760.015 * 0.10260.013 *
Lysine 0.37060.090 b 0.29260.064 b 0.77760.062 {a 0.54760.043 {a 0.28660.068 b 0.25560.063 b
Methionine 0.13360.021 0.16060.018 a 0.14960.020 { 0.08360.007 {b 0.11960.013 0.09660.011 b
Phenylalanine 0.06260.009 0.06360.008 0.07360.004 { 0.05560.004 { 0.06160.006 n 0.04760.005 n
Serine 0.10260.015 b 0.10260.015 b 0.18760.015 a 0.16460.013 a 0.11860.015 b 0.09960.012 b
Taurine 0.74960.069 b 0.86360.067 b 1.33360.117 a 1.50160.107 a 0.53860.38 b 0.4936.020 b
Threonine 0.29860.052 0.30660.040 0.28260.018 0.23760.028 0.38860.294 n 0.28760.029 n
Tryptophan 0.07960.012 b 0.08260.012 0.10760.005 *a 0.08360.008 * 0.07860.006 b 0.06760.008
Tyrosine 0.07160.013 0.07760.012 0.07860.007 * 0.05760.004 * 0.07760.008 * 0.05960.003 *
Valine 0.23560.037 0.19560.026 0.26160.013 { 0.16260.015 { 0.23860.024 { 0.14860.015 {
Branched chain 0.49260.048 0.41560.053 0.56360.028 { 0.36460.034 { 0.49360.05* 0.32660.048*
Essential 1.43460.240 1.31760.182 1.98660.123 {a 1.36760.104 { 1.42560.126 nb 1.07960.143 n
Non-essential 2.21560.332 b 2.46560.266 3.55260.228 a 3.45760.202 a 2.17860.173 b 1.85960.112 b
Total 3.65060.563 b 3.78160.436 5.53860.318 a 4.84260.291 a 3.60460.243 nb 2.93860.242 nb
Values shown with SEM. Differences between diet treatment at individual time points represented by * = P,0.05; {=P,0.01; {= P,0.001; trend n=p,0.1. Differences
between time points within the same diet group represented by different letter (P,0.05).
13.5 days NPD: n = 14 for Alanine, Threonine, essential, non-essential and total amino acids.
doi:10.1371/journal.pone.0052791.t001
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in particular AA composition within maternal serum, UF and
blastocysts (the first such comparative analysis reported) and
associated effects on embryo phenotype and signalling activity,
implicate insulin and AA composition as primary upstream factors
contributing to developmental programming.
Insulin is known to stimulate mouse preimplantation embryo
biosynthesis, proliferation, endocytosis and subsequent fetal
growth [37,41,42,48] while hyperglycaemia and maternal diabetes
compromise early development [49,50]. AAs likewise have a
beneficial effect on early embryo development, contributing to
biosynthesis and proliferation as well as protective mechanisms
against osmotic, metal ion and reactive oxygen stresses; essential
AAs are particularly supportive of development during morula and
blastocyst stages [36,39,51]. Emb-LPD caused reduced insulin and
increased glucose levels in maternal serum at the time of blastocyst
formation (E3.5) together with reduced concentrations of 10
individual AAs and the collective concentration of essential AAs
and the branched chain AAs (leucine, isoleucine and valine). We
also found estrogen to be elevated by Emb-LPD but only by E4.5
and no changes in progesterone or corticosterone concentration
were identified.
The mild maternal hyperglycemia and AA depletion mirrors
our data from an earlier study of Emb-LPD treatment in the rat
including a consistent serum phenotype of depleted essential and
branched chain AAs at the time of blastocyst formation [14]. In
the current study, we have been able to include AA analysis of UF
in relation to maternal diet, collected during the period of
blastocyst formation and expansion and likely to be representative
of the most immediate environment change experienced by
embryos. Our UF data show broad similarity in relative AA
composition to that reported previously for non-pregnant,
naturally cycling mice [51] although individual concentrations
Table 2. Uterine fluid concentrations of free amino acids from mice fed either NPD or Emb-LPD at 2.5, 3.5 or 4.5 days of
pregnancy.
Amino acid Concentration (mM)
2.5 days 3.5 days 4.5 days
Amino Acid NPD Emb-LPD NPD Emb-LPD NPD Emb-LPD
n 9–101 10 9–121 9–131 10–151 6–151
Alanine 1.20860.247 b 1.33360.235 b 3.80360.214 a 3.32160.206 a 0.72660.192 b 0.73660.198 b
Arginine 0.19160.021 0.18960.021 a 0.16160.019 0.14260.018 0.12860.017 0.11960.017 b
Asparagine 0.11660.015 0.12060.015 0.14260.014 0.14060.013 0.10560.013 0.11660.013
Aspartic acid 1.47660.147 1.57460.147 1.83360.134 a 1.54260.129 1.25360.120 b 1.17260.120
Glutamic acid 3.76660.344 3.83460.344 4.72160.314 a 4.04960.301 3.47160.280 b 3.44360.280
Glutamine 0.89460.100 a 1.07460.100 1.41760.091 b 1.21760.088 0.92760.082 a 0.97360.082
Glycine 2.98560.302 a 3.46060.287 a 2.67660.262 na 2.25360.252 nb 1.34860.023 b 1.46860.234 b
Histidine 0.28160.028 a 0.26660.028 a 0.14760.025 nb 0.10860.024 nb 0.08960.023 b 0.09260.023 b
Isoleucine 0.20760.019 0.19660.019 a 0.21260.018 * 0.16360.017 * 0.16260.016 * 0.13360.016 *b
Leucine 0.42560.033 a 0.41160.033 a 0.32460.030 { 0.24360.029 {b 0.26660.027 *b 0.21560.028 *b
Lysine 0.39660.052 0.39260.052 0.52160.047 n 0.50760.046 n 0.45960.042 0.50260.042
Methionine 0.15260.025 0.20560.025 0.18460.023 0.21560.022 0.19660.020 { 0.27160.020 {
Phenylalanine 0.16960.015 a 0.16760.015 a 0.13960.014 0.11760.014 0.10060.013 b 0.09760.013 b
Serine 0.66760.135 0.73160.135 0.96660.123 a 0.76460.019 0.41860.110 b 0.42260.110
Taurine 11.75761.302 13.51761.302 14.74461.372 n 12.08961.372 n 12.70961.302 11.14761.681
Threonine 0.30560.056 a 0.32660.056 a 0.72660.051 nb 0.57960.049 nb 0.50060.046 c 0.42160.046
Tryptophan 0.04960.014 0.04660.014 0.06160.013 0.06660.012 0.07460.012 0.05960.012
Tyrosine 0.41860.173 a 0.34060.073 0.18260.067 b 0.20860.064 0.33260.060 0.19860.060
Valine 0.62060.044 a 0.50860.044 a 0.45760.040 {b 0.31160.039 {b 0.35860.036 {b 0.26960.036 {b
Branched chain 1.25260.090 a 1.11660.090 a 0.99360.082 { 0.71660.079 {b 0.78560.073 b 0.59460.076 b
Essential 2.32160.197 2.25160.197 2.62360.180 * 2.20160.173 * 2.11460.161 1.91260.161
Non-essential 23.86362.217 26.43862.104 31.09862.217 *a 24.72462.217 * 21.63162.104 b 19.22162.716
Total 26.04462.365 28.68962.244 33.74762.365 a 26.63962.365 23.73962.244 b 21.08262.897
Values shown with SEM. Differences between diet treatment at individual time points represented by * = P,0.05; {=P,0.01; {= P,0.001; trend n= P,0.1. Differences
between time points within the same diet group represented by different letter (P,0.05).
12.5 days NPD: n = 9 for Alanine, Glycine, non-essential and total amino acids; 3.5 days NPD and Emb-LPD: n = 9 for Taurine, non-essential and total amino acids; 4.5 days
NPD and Emb-LPD: n = 10 or 6 for Taurine, non-essential and total amino acids; 4.5 days Emb-LPD: n = 14 for Alanine, Leucine, essential and branched amino acids.
doi:10.1371/journal.pone.0052791.t002
Figure 2. Aminograms in compartments at different time points following Emb-LPD and NPD treatments. (A) Maternal serum, (B)
uterine fluid at days 2.5, 3.5 or 4.5 and (C) blastocysts at day 3.5 as taken from Tables 1, 2, 3.
doi:10.1371/journal.pone.0052791.g002
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are some 1.5–4 times higher in the current study, possibly
reflecting the difference in strain, pregnancy state and method of
UF collection. Comparative analysis between serum and UF
composition demonstrates that of the ten AAs depleted in Emb-
LPD serum at E3.5 days, only three of these, the branched chain
essential AAs, leucine, isoleucine and valine, remain significantly
depleted in Emb-LPD UF at this time point. Whilst serum and UF
AA concentrations were found not to be different with respect to
diet at E2.5, presumably reflecting the short duration of dietary
challenge at that time, the data at E4.5 confirmed that obtained at
E3.5 with only the three branched chain AAs significantly depleted
in UF. Moreover, it is worth emphasising that Emb-LPD induces a
global reduction in AA concentration available to embryos in both
serum and UF datasets. For example, at E3.5, 16 of the 19 AAs
analysed in serum and UF showed mean concentrations reduced
following Emb-LPD versus NPD. However, whilst global reduc-
tions in AA concentrations are evident at E3.5, and in particular
for the branched chain AAs, methionine concentration was
elevated in response to Emb-LPD in UF at all three time points
and significantly so at E4.5.
The changing patterns of branched chain and methionine AA
concentration with respect to diet in serum and UF pools have
potential to be contributory to developmental programming
mechanisms. Previously, we showed that blastocysts transferred
at E3.5 from Emb-LPD mothers to NPD recipients exhibited
stimulated growth in late gestation, an early marker for adult
disease [15]. This indicates that AA concentrations evident in UF
at this time point are more likely to be influential in programming
mechanisms. The consistency in branched chain AA concentra-
tion depletion across serum and UF during blastocyst formation
also previously shown in the rat study [14] together with the
concurrent reduction in maternal insulin all implicate mTORC1
complex signalling in blastocyst programming. Branched chain
AAs (especially leucine) and insulin activate cellular growth and
proliferation to match nutrient availability via mTORC1 serine-
threonine kinase which increases the initiation of translation of
cap-dependent and terminal oligopyrimidine (TOP)-dependent
mRNAs through phosphorylation of the major downstream
targets 4E-BP1 and S6 kinase [43–45,47]. AAs may activate
mTORC1 via poorly-defined extracellular or intracellular sensor
mechanisms [47,52] while insulin acts directly through the insulin
Table 3. Blastocyst free amino acid concentration and relative % at day 3.5 of pregnancy from mice fed either NPD or Emb-LPD
from morning after mating.
Amino acid levels at E3.5
Concentration (mM) Relative (%)
Amino Acid NPD Emb-LPD NPD Emb-LPD
n 14–161 13–191 14 13
Alanine 1.91060.264 1.59060.229 3.69060.220 3.76060.370
Arginine 1.21060.308 0.77760.0934 2.52060.390 2.01060.230
Aspargine 1.20060.149 * 0.83260.107 * 2.56060.170 2.27060.170
Aspartic acid 4.86060.551 3.90060.325 10.80060.680 10.80060.270
Glutamic acid 9.7161.160 7.89060.759 19.50060.900 * 22.30060.710 *
Glutamine 1.66060.253 1.37060.178 3.24060.320 3.33060.210
Glycine 1.72060.174 1.45060.177 3.73060.310 3.15060.220
Histidine 4.50060.506 4.50060.548 9.09060.750 9.55060.460
Hypotaurine 2.07060.308 n 1.45060.206 n 4.31060.420 4.11060.260
Isoleucine 0.32960.036 0.29560.031 0.70060.030 0.74060.040
Leucine 0.73660.086 0.58660.044 1.51060.080 1.54060.130
Lysine 1.00060.151 n 0.70860.137 n 2.12060.230 * 1.45060.100 *
Methionine 1.08060.096 1.22060.123 2.25060.140 { 3.43060.220 {
Phenylalanine 0.23960.024 0.35160.055 0.55060.050 * 0.72060.050 *
Serine 1.87060.199 1.71060.171 4.04060.310 4.25060.280
Taurine 12.20061.210 n 9.49061.050 n 25.10061.200 * 22.10060.840 *
Threonine 0.84260.096 0.78960.081 1.66060.140 1.93060.080
Tyrosine 0.39960.088 0.31160.063 0.89060.300 0.56060.020
Valine 0.88760.084 0.78560.061 1.85060.040 n 1.98060.050 n
Branched chain 1.9560.199 1.67060.128 4.06060.120 4.26060.200
Essential 4.98060.501 4.84060.400 10.60060.230 * 11.80060.420 *
Non-essential 41.40064.730 33.50063.630 89.40060.230 * 88.20060.420 *
Total 46.30065.240 39.40064.100
Values shown with SEM. Differences between diet treatment at individual time points represented by * = P,0.05; {= P,0.01; {= P,0.001; n= trend, P,0.1.
1NPD: n = 15 for Phenylalanine, essential amino acids and n = 14 for Hypotaurine, non-essential and total amino acids; Emb-LPD: n = 18 for Lysine, Methionine, Tyrosine,
n = 17 for Alanine, Histidine, Phenylalanine, n = 16 for essential amino acids, n = 15 for Hypotaurine, n = 14 for non-essential amino acids, n = 13 for total amino acids.
doi:10.1371/journal.pone.0052791.t003
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receptor and IRS/PI3K/AKT/mTORC1 pathway [53]. Thus,
the combined deficiency in leucine, other branched chain AAs and
insulin concentrations in the embryo environment following Emb-
LPD may act upstream as negative maternal regulators of nutrient
sensing leading to developmental programming. Moreover,
mTORC1 signalling mediated through leucine and arginine is
activated in blastocysts to control trophoblast motility [38–40] and
embryos null for the mTOR gene arrest at E5.5 with implantation
failure [54].
We evaluated directly the effect of Emb-LPD on blastocyst
mTORC1 signalling using antibodies to detect relative pools of
phosphorylated and total 4E-BP1 and S6 protein. This analysis
demonstrated that blastocysts from Emb-LPD mothers at E3.5
had equivalent amounts and ratio of phosphorylated and total 4E-
BP1 to controls from NPD mothers. However, Emb-LPD
blastocysts had deficient phosphorylated S6 and its ratio to total
S6 protein was reduced compared with NPD controls. Thus, the
suppressed levels of insulin and/or AA mTORC1 activators in
vivo is clearly sensed by Emb-LPD blastocysts via the S6 effector
even after collection and analysis in vitro. Phosphorylated S6 (40S
ribosomal protein) acts to stimulate translation of TOP mRNAs
which commonly encode translation factors including ribosomal
proteins [47]. Whilst both S6 and 4E-BP1 effectors are usually
receptive simultaneously in mTORC1 signalling studies, differen-
tial responsiveness has been previously reported. Thus, loss of S6
but not 4E-BP1 phosphorylation in response to direct mTORC1
inhibition occurred in urothelial carcinoma lines whereas addi-
tional upstream inhibition of PI3K/AKT was required for 4E-BP1
inhibition [55]. Indeed, recent models of mTORC1 effector
function suggest distinct biological roles and signalling pathways
for the two main effectors S6 and 4E-BP1 [56,57] as in the current
study.
The increase in methionine detected only at 4.5 days in UF may
also be pertinent as a contributory factor to onset of developmental
programming. LPD, when administered from 2 weeks before
mating, has been shown to increase serum homocysteine in mice
at the time of blastocyst formation which may in turn lead to folate
deficiency and reduced genomic methylation [58]. Homocysteine
elevation in this study was proposed to derive from significantly
reduced threonine availability to drive its re-methylation to
methionine [58]. Reduced serum threonine was detected following
LPD in our previous rat study [14] but was only evident at trend
level in the current study in serum and UF; however the increase
in Emb-LPD UF methionine at E4.5 may be symptomatic of this
conversion.
The analysis of blastocyst AA composition (Table 3) revealed a
distinct pattern compared with that of maternal serum and UF.
This pattern of relative concentration is consistent with those from
earlier studies of AA content in mouse blastocysts which reported
high concentrations of taurine, glutamic acid and aspartic acid
Table 4. Fold changes in concentrations (mM) of free amino acids within serum, uterine fluid and blastocyst compartments at day
3.5 with respect to maternal diet (NPD, Emb-LPD).
Fold change in amino acid concentration (mM) between compartments
UF/serum blastocyst/UF blastocyst/serum
Amino Acid NPD Emb-LPD NPD Emb-LPD NPD Emb-LPD
Alanine 7.217 8.416 0.502 0.479 3.625 4.029
Arginine 0.913 1.025 7.516 5.472 6.860 5.608
Asparagine 3.276 3.438 9.155 5.943 3.276 20.432
Aspartic acid 43.109 34.800 2.979 2.529 128.410 88.014
Glutamic acid 25.432 19.254 2.288 1.949 58.179 37.519
Glutamine 2.410 2.107 1.291 1.126 3.112 2.372
Glycine 9.368 8.176 0.717 0.644 6.722 5.262
Histidine 1.956 2.020 32.041 41.667 62.681 84.146
Isoleucine 1.779 2.058 1.736 1.810 3.087 3.724
Leucine 1.767 1.986 2.457 2.412 4.341 4.789
Lysine 0.671 0.926 2.534 1.397 1.699 1.294
Methionine 1.236 2.600 6.467 5.674 7.991 14.753
Phenylalanine 1.908 2.149 1.719 3.000 3.280 6.446
Serine 5.173 4.660 2.453 2.238 12.691 10.429
Taurine 11.059 8.056 0.902 0.785 9.976 6.324
Threonine 2.575 2.446 1.336 1.363 3.441 3.334
Tryptophan 0.564 0.801
Tyrosine 2.332 3.624 2.236 1.495 5.215 5.419
Valine 1.752 1.920 2.158 2.524 3.780 4.845
Branch chain 1.748 1.969 2.165 2.332 3.464 4.588
Essential 1.191 1.427 1.899 2.267 2.700 3.767
Non-essential 8.756 7.164 1.502 1.354 11.656 9.708
Total 6.205 5.607 1.374 1.482 8.528 8.309
Values based upon means used in Tables 1, 2 and 3.
doi:10.1371/journal.pone.0052791.t004
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[59,60]. Here, whilst a global depletion in individual AA
concentration in blastocysts was apparent at E3.5 in response to
Emb-LPD (17 of 19 AAs analysed) together with reduced pools of
essential, non-essential, branched chain and total AA concentra-
tions, these were not significant, reflecting greater variation
between samples. A significant reduction in asparagine concen-
tration was, however, detected in Emb-LPD blastocysts. Aspara-
gine was only reduced at trend level in Emb-LPD serum at E4.5
and not affected by diet in UF. Further, hypotaurine, lysine and
taurine were reduced in Emb-LPD blastocysts at trend level
compared with NPD. These AAs have been shown either to be
consumed by blastocysts or to be supportive of their development
[61–66] and so may also contribute to diet-induced altered
blastocyst phenotype and potential.
The blastocyst AA composition indicated that despite the
reduced maternal availability of branched chain AAs by Emb-
LPD and the accompanying reduction in mTORC1 signalling,
these AAs were nonetheless present within blastocysts at near
normal concentrations. This distinction indicates the importance
of these AAs to blastocyst metabolism and presumably reflects an
altered blastocyst uptake rate or transporter expression profile to
compensate. It is thought nutrient sensing via mTORC1 may be
mediated at cell surface or intracellular sites [47,52] thereby
allowing both mTORC1 signalling and compensatory activity to
occur concurrently.
Figure 3. Aminograms of compartments relative to each. (A) Emb-LPD and (B) NPD treatments on day d3.5 as taken from Table 4.
doi:10.1371/journal.pone.0052791.g003
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Comparative analysis of the serum, UF and blastocyst AA
concentrations within a single study has not been reported
previously and demonstrates the dynamic and regulated nature
of these pools with significant fold changes occurring between
them (Table 4; Figure 4). Total and most individual AAs increase
in concentration from serum to UF (,6 fold) and from UF to
blastocyst (,1.4 fold), a trend previously reported [51,59] and
reflecting the regulatory epithelial transport boundaries provided
by endometrium and trophectoderm [39,67,68]. Whilst the
biological contribution of these changing pools to reproductive
function has been reviewed previously, it is worth emphasising the
importance of AA composition in culture media reflecting in vivo
conditions close to the embryo [51]. We are currently utilising the
UF AA composition (Table 3) in in vitro studies on developmental
potential.
A final component of our AA analysis was to construct
aminograms of the AA concentration in the three compartments
(serum, UF, blastocysts) with respect to diet (Figure 2). These
facilitate comparison of pattern of AA concentration change across
the compartments and with respect to time points used. Notably,
the serum aminogram revealed a transient peak in the more
abundant AAs (taurine, lysine, glutamine, alanine, glycine) at E3.5
relative to E2.5 and E4.5 (Figure 2A). However, this pattern was
generally not maintained within UF except for alanine and
partially for glycine (occurring at ,7-fold and ,9-fold higher
concentration in UF relative to serum, respectively). Alanine and
glycine are both supportive of embryo development and facilitate
osmoregulation to provide cell volume control in late cleavage [69]
and their high local concentration may become critical to maintain
cell volume around the time of blastocyst formation when fluid
transport into the embryo is active. The compartment amino-
grams also show multi-fold increased levels of glutamic acid and
aspartic acid in UF and blastocysts relative to serum and histidine
in blastocysts relative to serum and UF. Glutamic and aspartic
acids are recognised abundant constituents of maternal tract fluid
[51] and their concentration in blastocysts will likely reflect this.
Histidine, through conversion to histamine, indirectly contributes
to blastocyst-uterine signalling at implantation [70] and is further
implicated in blastocyst growth [71].
Figure 4. Maternal diet effects on mTORC1 signalling. Quantitative immunoblotting of mTORC1 downstream targets (A–C) S6 protein, (D–F)
4E-BP1 protein normalised to a-tubulin. Representative blots for (A) total S6; (B) phosphorylated S6; (C) relative intensity of total, phosphorylated and
ratio of S6 in Emb-LPD and NPD blastocysts; (D) total 4E-BP1; (E) phosphorylated 4E-BP1; (C) relative intensity of total, phosphorylated and ratio of 4E-
BP1 in Emb-LPD and NPD blastocysts. Individual blot lanes include MW markers (left) and samples of Emb-LPD (L) and NPD (N) blastocysts (25
blastocysts per lane) and loading control (LC, pooled blastocysts at 25 per lane). * P,0.05, n = 8 samples per treatment.
doi:10.1371/journal.pone.0052791.g004
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Our analysis of blastocyst and outgrowth phenotype in response
to Emb-LPD revealed that TE and total cell numbers increased at
3.75 days and that outgrowth spreading increased over 48–
72 hours following culture of blastocysts (Figure 5). The increase in
blastocyst cell numbers did not include those within the ICM
which were slightly lower at E3.75 than at E3.5 in both treatment
groups. ICM cell number in this strain of outbred mice (MF1) does
not increase synchronously with time during blastocyst expansion
reflecting the cell cycle duration (,12 hr) and relative position of
individual cells within that cycle [72]; this may explain the absence
of proliferation in the ICM over the two time points used. The
preferential increased proliferation of the extra-embryonic TE
cells and their subsequent increased motility may be viewed as an
early compensatory response to poor diet to enhance early
trophoblast invasive capacity at implantation. Indeed, evidence of
compensatory placental morphological organisation and transport
activity in response to LPD in later gestation was reported recently
[73]. This early response would augment the compensatory
activity we identified previously in endocytotic activity and
receptor expression of the extra-embryonic visceral endoderm
lineage in late gestation in response to Emb-LPD and LPD. Our
blastocyst cell number analysis is also broadly consistent with an
earlier mouse study where maternal dietary protein level was
reduced from 3–4 weeks before mating resulting in a reduced
blastocyst ICM/TE ratio [74]. However, in our rat model, both
ICM and TE cell numbers were reduced by Emb-LPD which may
indicate a species difference in TE response coinciding with
compensatory growth occurring later than in the mouse, mainly
postnatally [14]. The spreading activity was found to be
rapamycin-insensitive in Emb-LPD outgrowths while rapamycin
was effective in inhibiting spreading in control samples but only at
the higher dose used (20 mM). The mTORC1 in mouse
blastocysts, shown to be responsive to leucine and arginine to
induce rapamycin-sensitive outgrowth activity, has some unusual
characteristics in that the complex subunit, LST8, is down-
regulated just at the time of kinase activation in the blastocyst and
the downstream effectors 4E-BP1 and S6K phosphorylation
patterns do not always correlate to outgrowth competency [40].
Moreover, the relatively high concentration of rapamycin, an
allosteric inhibitor of mTORC1, required in the current study to
demonstrate the diet-related difference in spreading activity is
unusual although the threshold of rapamycin sensitivity is variable
in different cellular models and evidence of mTORC1 resistance
can be explained by reduced capacity to induce or maintain 4E-
BP1 dephosphorylation [75]. This may indicate that enhanced
activity in Emb-LPD outgrowths may be mediated through the
4E-BP1 pathway, through undefined interactions of the unusual
blastocyst mTORC1 or 2 complex, through compensatory
feedback loops involving insulin, AKT and mTORC1 and 2
signaling or through loss of rapamycin-sensitivity of one or both
mTORC complexes after prolonged exposure. Alternatively, the
induction of enhanced trophoblast migration by Emb-LPD may
occur either via other related signalling components such as the
energy sensing AMPK [76] or earlier, prior to blastocyst
collection, since UF from the time of blastocyst expansion is
competent to induce subsequent outgrowth activity in medium
lacking AAs [40].
In conclusion, we have investigated mechanisms of early
induction of adverse long-term developmental programming
mediated through Emb-LPD. We provide evidence that dietary-
mediated changes in maternal metabolites and AAs, including a
reduction in branched chain AA availability in the immediate
environment experienced by blastocysts during their formation,
may act as a nutrient sensing mechanism for the embryos. We
Figure 5. Maternal diet effects on blastocysts and outgrowths.
(A) Emb-LPD and NPD blastocyst maturity at E3.5. n = 13–15 mothers
per treatment. (B) Emb-LPD and NPD blastocyst cell number at E3.5 and
E3.75 within trophectoderm (TE) and ICM and total pools, * P,0.05.
n = 135–156 embryos from 11–12 mothers. (C) Representative bright-
field image of blastocyst outgrowth showing trophoblast (TB) and ICM
cells and with perimeter line included for area measurement, plus
corresponding DAPI image for nuclei; Scale bar = 20 mm. (D) Area of
outgrowths at 72 h culture, * P,0.05. n = 34–41 per treatment. (E) Area
increase during 48–72 h culture, expressed as % change from 48 h, in
different concentrations of rapamycin, different letters or * P,0.05.
n = 18–23 per treatment.
doi:10.1371/journal.pone.0052791.g005
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show that this altered environment associates with a reduced
mTORC1 signalling capacity and AA content within Emb-LPD
blastocysts. Lastly, we show that changes in blastocyst phenotype,
notably increased TE proliferation and outgrowth invasiveness
behaviour occur in response to Emb-LPD that can be interpreted
as early compensatory mechanisms. The stimulation in fetal and
postnatal growth as an early marker of adult disease mediated
through Emb-LPD and shown to be induced by the blastocyst
stage [15] likely reflects first accurate sensing of environmental
nutrients by embryos and second activation of compensatory
mechanisms. Whilst we interpret altered mTORC1 signalling as
an appropriate sensing mechanism and altered TE phenotype as
an early compensatory mechanism, we envisage concurrent
modulation in embryo metabolism that will convert the negative
mTORC1 signal into a positive biosynthetic response to drive
compensatory growth. The nature of such modulation in embryo
metabolism is currently being investigated.
Materials and Methods
Animal Treatments
All mice and experimental procedures were conducted using
protocols approved by, and in accordance with, the UK Home
Office Animal (Scientific Procedures) Act 1986 and local ethics
committee at the University of Southampton under UK Home
Office Project Licence PPL30/2467. MF1 mice, under UK Home
Office licence and local ethics approval, were bred in-house
(University of Southampton) on a 0700–1900 light cycle with
standard chow. Virgin females (7–8.5 weeks) were mated naturally
overnight with MF1 males and plug positive females housed
individually the following morning and assigned without prefer-
ence to either (a) normal protein diet (NPD, 18% casein) or (b) low
protein diet (Emb-LPD, 9% casein) (Special Diet Services, Lillico
Biotechnology, UK) for up to E4.5. Diets were isocaloric and their
full composition has been described previously [15,77].
Metabolic Assays
Serum was derived from maternal blood after culling and heart
puncture at E3.5 and 4.5 in both diet treatment groups and stored
at 280uC before use in metabolic assays. Glucose concentrations
were determined using the glucose oxidase GOD-Perid method
with a Cobas-Mira S autoanalyser (Roche Instruments, UK).
Insulin was measured using the rat insulin sandwich ELISA kit
(Crystal Chem International, IL, USA) and a Dynatech MR5000
plate reader. Corticosterone was measured using an 125I RIA kit
(ICN Biomedicals, UK) and a 1274 RiaGamma counter (LKB-
Wallac, Finland). Estrogen was determined using the 3rd
Generational Estradiol RIA kit (DSL, UK) and progesterone
using the 17a-OH progesterone 125I RIA kit (DSL, UK), both
counted using a 1274 RiaGamma counter.
Collection of Uterine Luminal Fluid
Following Emb-LPD or NPD treatment for up to E4.5, females
were culled by cervical dislocation and uterine fluid (UF) was
collected by direct sampling. Each uterine horn was ligated at the
posterior end close to the cervix during dissection before cutting
away from the oviduct. The free uterine ends were washed in ice-
cold phosphate buffered saline (PBS) and blotted before removing
one ligature and gently inserting a collection pipette (see below)
into the lumen down to the cervical junction and slowly removing
it with UF collected by capillary action. This was repeated for the
other horn. The collection pipette was constructed from a flame-
pulled region (,0.5 mm outer diameter) of a Pasteur pipette,
subsequently flame-polished at the tip and calibrated using diluted
[14C]-sucrose to relate internal pipette fluid volume determined by
microscopy using an eyepiece graticule with radioactivity using an
LS6500 Gamma counter (Beckman, UK). The volume of collected
UF was recorded before diluting in PBS up to 13 ml, centrifuging
at 10,000 g for 10 min at 4uC to remove any cellular contents, and
supernatant (10 ml) and pellet (3 ml) samples stored at 280uC. UF
pellet samples were examined for cellular content by immunocy-
tochemistry using epithelial and macrophage antibodies; cellular
detection was minimal, predominantly epithelial cells, approxi-
mating 5 cells/sample with no relationship evident with maternal
diet treatment (data not shown).
Embryo Collection and Treatments
Embryos were collected at different times during dietary
treatment from mothers by cervical dislocation, dissection of
reproductive tract and flushing of embryos using H6 medium
supplemented with 4 mg/ml BSA (H6-BSA) [9]. For analysis of
free amino acid composition, blastocyst stage and diameter were
assessed (early, mid, expanded) followed by three thorough washes
in PBS supplemented with 0.1% PVA before flash-freezing in
groups of 8–10 (separated by per mother) in 10 ml of HPLC-grade
water in HPLC-vials on dry ice as rapidly as possible. This
procedure took less than 10 min per mother and wash drop
analysis showed no or background traces of AA even if embryos
were left for up to 30 min suggesting no or negligible leakage
during the collection process.
For assessing cell numbers, embryos were subjected to
differential nuclear labeling after complement-mediated lysis of
the trophectoderm [78] with modifications. Briefly, embryos were
placed in 10% tetranitrobenzene sulphonic acid (TNBS; Sigma,
UK) in H6+0.1% PVA for 10 mins, washed 3 times in H6-BSA,
incubated in 0.4 mg/ml rabbit anti-dinitrophenyl (anti-DNP)
antibody (Sigma, UK) in H6-BSA for 10 mins, washed in H6-
BSA and incubated in a 25 ml drop of reconstituted Low-Tox
guinea pig complement (1:10 dilution, Cedarlane, Canada) with
2 ml propidium iodide (PI; Sigma, 1 mg/ml) for 10 mins at 37uC.
Embryos were washed in H6-BSA, fixed in ethanol plus 1%
bisbenzimide (Sigma) at 4uC, washed in fresh ethanol, mounted in
glycerol on a glass slide, viewed on a Zeiss Axiophot upright
epifluorescent microscope and nuclei counted using Metamoph
software (Version 6.2r6).
To evaluate further development and outgrowth potential,
blastocysts were placed individually into 20 ml drops of KSOMu-
faa supplemented with 10% FCS (KSOMufaa+FCS) under oil and
allowed to attach and spread for up to 120 h. KSOMufaa
comprises KSOM medium (Sigma) supplemented with the mean
composition of AAs identified in the UF of NPD mothers at E3.5
(Table 2). Morphology and attachment of blastocysts were assessed
at daily intervals using a Zeiss Axiovert inverted microscope fitted
with environment chamber at 37uC, and brightfield images taken
every 24 h for area measurements using Metamorph software.
Blastocyst outgrowth was also conducted for specific periods with
medium containing rapamycin (2 or 20 mM; LC laboratories,
Woburn, USA) or vehicle (0.05% DMSO) to inhibit mTORC1
activity.
Amino Acid Analysis
Serum and UF concentrations of 19 AAs were determined using
a Kontron 500 series automated reverse phase high performance
liquid chromatography system equipped with a Jasco F920
fluorescence detector and a 4.5 mm6250 mm Hypersil ODS-16
column (Jones Chromatography, Glamorgan, UK). Serum and
UF samples were diluted from 1/12.5 to 1/112.5 with PBS or
HPLC grade water (Fisher Scientific, UK) dependent upon sample
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type and AAs to be detected; derivatized (precolumn) with o-
phthaldialdehyde [51], D-homoserine and a-amino butyric acid;
run in duplicates and compared with 10 mmol l21 AA standards.
For blastocyst AA analysis, a 4.6 mm6250 mm Hyperclone 5u
ODS (C18) 120A column (Phenomenex, Macclesfield, UK) was
employed. Samples were diluted 1:1 with HPLC grade water and
compared to 10 mM standards and negative controls (washing
medium and HPLC water). For calculating absolute concentra-
tions, blastocyst volume was taken into account for each sample.
Blastocyst mTORC1 Activity
Blastocysts were collected from diet-treated mothers at E3.5 and
transferred to SDS sample buffer containing protease (Roche
cOmplete mini protease inhibitor cocktail, UK) and phosphatase
(Sigma Phosphatase Inhibitor Cocktails 1 and 2, Poole, UK)
inhibitors, boiled and stored at 280uC in 25 embryos/15 ml
aliquots for each diet treatment (,10 blastocysts collected per
mother following natural mating). Samples were re-boiled and run
on 4–12% bis-tris gels (Invitrogen, UK), transferred onto
nitrocellulose membrane overnight, blocked in 5% milk in TBS-
Tween (0.1% Tween 20) for 1 h before incubation in primary
antibodies overnight at 4uC. All primary antibodies were from Cell
Signaling (Invitrogen, UK), made up in 5% BSA in TBS-Tween
(total S6 ribosomal protein(5G10) #2217 1:2000; phospho-S6
ribosomal protein(Ser235/236) #4858 1:2000; total 4E-BP1
#9452, 1:500–1000; phospho-4E-BP1(Thr37/46) #9459 1:500–
1000; a-tubulin #2144 1:10,000) with 25 blastocysts equivalent
per lane, split from a pool of 50, for total protein and
phosphorylated protein blotting respectively of S6 and 4E-BP1
with a-tubulin used as control protein. Inter-gel variation was
normalized by running a standard pooled blastocyst sample (25
equivalent per lane) on all gels. Blots were washed in TBS-Tween
and incubated in appropriate IRDye-conjugated secondary
antibodies (Molecular Probes, Invitrogen, UK), washed and
membranes analysed by densitometry using an Odyssey Infrared
Imaging System (Licor).
Statistics
Amino acid composition, embryo cell numbers and outgrowth
spreading were analysed using one-way ANOVA or two-way
ANOVA (day or drug and diet treatment as factors) followed by
appropriate post hoc tests (Bonferroni or Mann-Whitney Rank
sum test if data were not normally distributed; SigmaPlot software
package version 12.1 and 12.2). All western blotting data were
assessed for normality and analysed by t-test (SPSS version 16).
Significance was assumed at P,0.05.
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